About Cogent Biosciences Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.cogentbio.com/
Frequently Asked Questions
What is the 52-week range for COGT?
The 52-week high is $43.73 and the 52-week low is $13.78.
What is the P/E ratio for COGT?
The P/E ratio data is currently unavailable.
What is the dividend yield for COGT?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -72.57%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -264.08%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 8.49.
Analyst Recommendation Trends
Wall Street analyst consensus for COGT over the last few months:
Latest COGT News
$1000 Invested In Cogent Biosciences 5 Years Ago Would Be Worth This Much Today
Cogent Biosciences (NASDAQ:COGT) has outperformed the market over the past 5 years by 16.44% on an annualized basis producing an average annual return of 28.63%. Currently, Cogent Biosciences has a market capitalization
Cogent Biosciences (COGT) Stock Trades At A Premium As FDA Accepts NDA
Cogent Biosciences has delivered very strong share price gains over the past five years, so the obvious question for you now is whether that move is backed up by what sits on its balance sheet. After a powerful run and fresh regulatory progress, investors are increasingly asking how today’s valuation stacks up against the company’s book value. Over the past 5 years the stock is up about 2.7x. This puts real pressure on the question of whether the current price is still in line with what its...
Cogent Biosciences (COGT) Looks Fully Valued Following FDA NDA Acceptance
Cogent Biosciences (COGT) just received U.S. Food and Drug Administration acceptance of its New Drug Application for bezuclastinib in Advanced Systemic Mastocytosis, with no advisory committee planned and no review issues flagged. Despite the FDA momentum, Cogent Biosciences shares have eased recently, with the 30 day share price return down 13.3% and the 90 day share price return down 17.4%. However, the 1 year total shareholder return of 137.1% suggests earlier optimism around its broader...
Will FDA’s Streamlined Bezuclastinib Review in ASM Change Cogent Biosciences’ (COGT) Narrative?
Cogent Biosciences recently announced that the FDA has accepted its New Drug Application for bezuclastinib in Advanced Systemic Mastocytosis, set a PDUFA action date of June 29, 2027, and indicated no current plans for an advisory committee or identified review issues. The filing builds on pivotal APEX trial data showing clinically meaningful responses and durable clinical activity in Advanced Systemic Mastocytosis, while parallel NDA reviews in NonAdvanced SM and GIST point to a broader...
Here’s How Much You Would Have Made Owning Cogent Biosciences Stock In The Last 5 Years
Cogent Biosciences (NASDAQ:COGT) has outperformed the market over the past 5 years by 18.64% on an annualized basis producing an average annual return of 30.55%. Currently, Cogent Biosciences has a market capitalization
Wedbush Reiterates Outperform on Cogent Biosciences, Maintains $55 Price Target
Wedbush analyst David Nierengarten reiterates Cogent Biosciences (NASDAQ:COGT) with a Outperform and maintains $55 price target.
Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
NDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful responses and evidence of disease modification in patients with AdvSM PDUFA target action date set for June 29, 2027 WALTHAM, Mass. and BOULDER, Colo., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that the U.S. Food and Drug Administration (FDA) has accep
HC Wainwright & Co. Reiterates Buy on Cogent Biosciences, Maintains $55 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Cogent Biosciences (NASDAQ:COGT) with a Buy and maintains $55 price target.
FDA Accepts Cogent Biosciences' NDA For Bezuclastinib In Patients With Advanced Systemic Mastocytosis
NDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful responses and evidence of disease modification in patients with AdvSMPDUFA target action date set for June 29, 2027
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-08-27 | Morris Arlene | -3,583 | - | - |
| 2026-08-27 | Morris Arlene | -41,927 | - | - |
| 2026-08-27 | Morris Arlene | -3,161 | $37.5396 | $118,663 |
| 2026-08-27 | Morris Arlene | -42,349 | $37.0925 | $1,570,830 |
| 2026-08-27 | Morris Arlene | +3,583 | $2.52 | $9,029 |
| 2026-08-27 | Morris Arlene | +41,927 | $5.64 | $236,468 |
| 2026-07-01 | Ferrante Karen Jean | +627 | - | - |
| 2026-06-09 | Shegog Todd | +17,901 | - | - |
| 2026-06-09 | Ros Matthew | +17,901 | - | - |
| 2026-06-09 | Harwin Peter Evan | +17,901 | - | - |
| 2026-06-09 | CAIN CHRISTOPHER W. | +17,901 | - | - |
| 2026-06-09 | Ferrante Karen Jean | +17,901 | - | - |
| 2026-06-09 | Morris Arlene | +17,901 | - | - |
| 2026-05-19 | Robbins Andrew R | +160,000 | - | - |
| 2026-05-19 | Robbins Andrew R | -160,000 | - | - |
| 2026-04-01 | Ferrante Karen Jean | +686 | - | - |
| 2026-03-31 | Fairmount Funds Management LLC | -28,000 | - | - |
| 2026-03-31 | Fairmount Funds Management LLC | -7,000,000 | $34.66 | $242,620,000 |
| 2026-03-31 | Fairmount Funds Management LLC | +7,000,000 | - | - |
| 2026-01-22 | Fairmount Funds Management LLC | -3,500,000 | $36.4 | $127,400,000 |
| 2026-01-01 | Ferrante Karen Jean | +643 | - | - |
| 2025-12-26 | Kearns Evan | -65,000 | $38.7 | $2,515,500 |
| 2025-12-26 | Green John L. | -77,000 | $38.68 | $2,978,360 |
| 2025-12-26 | Sachs Jessica | -82,642 | $38.7 | $3,198,245 |
| 2025-12-26 | Robinson John Edward | -90,000 | $38.74 | $3,486,600 |
| 2025-12-17 | Robinson John Edward | +65,000 | - | - |
| 2025-12-17 | Robinson John Edward | -139,998 | $39.45 | $5,522,921 |
| 2025-12-17 | Robinson John Edward | +320,000 | - | - |
| 2025-12-17 | Robinson John Edward | +50,000 | - | - |
| 2025-12-17 | Pinnow Cole | +65,000 | - | - |
| 2025-12-17 | Pinnow Cole | -94,800 | $39.45 | $3,739,860 |
| 2025-12-17 | Pinnow Cole | +214,000 | - | - |
| 2025-12-17 | Pinnow Cole | +50,000 | - | - |
| 2025-12-17 | Sachs Jessica | +65,000 | - | - |
| 2025-12-17 | Sachs Jessica | -154,716 | $39.45 | $6,103,546 |
| 2025-12-17 | Sachs Jessica | +320,000 | - | - |
| 2025-12-17 | Sachs Jessica | +50,000 | - | - |
| 2025-12-17 | Kearns Evan | +55,000 | - | - |
| 2025-12-17 | Kearns Evan | -125,602 | $39.45 | $4,954,999 |
| 2025-12-17 | Kearns Evan | +260,000 | - | - |
| 2025-12-17 | Kearns Evan | +40,000 | - | - |
| 2025-12-17 | Green John L. | +65,000 | - | - |
| 2025-12-17 | Green John L. | -145,007 | $39.45 | $5,720,526 |
| 2025-12-17 | Green John L. | +300,000 | - | - |
| 2025-12-17 | Green John L. | +50,000 | - | - |
| 2025-12-17 | Robbins Andrew R | +245,000 | - | - |
| 2025-12-17 | Robbins Andrew R | -367,497 | $39.45 | $14,497,757 |
| 2025-12-17 | Robbins Andrew R | +840,000 | - | - |
| 2025-12-17 | Robbins Andrew R | +185,000 | - | - |